EVA Pharma of Africa, DNA Script and Quantoom Biosciences have signed a memorandum of understanding (MoU) to establish the first digital-to-biologics, end-to-end mRNA production platform in Egypt.
It will focus on the production of nucleic acid-based vaccines and therapeutics.
Go deeper with GlobalData
The platform integrates technologies from all partners.
French company DNA Script will contribute its enzymatic DNA synthesis technologies, while Quantoom of Belgium will bring its Ntensify mRNA synthesis and Ncapsulate formulation technologies to the table.
EVA Pharma will leverage its expertise in vaccine development, GMP [good manufacturing practice] sterile manufacturing and commercialisation.
The partnership aims to provide a quick response to outbreaks of infectious disease and routine immunisations.
How well do you really know your competitors?
Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.
Thank you!
Your download email will arrive shortly
Not ready to buy yet? Download a free sample
We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form
By GlobalDataAiming to produce 100 million doses of RNA-based vaccines every year, this partnership aligns with Africa Centres for Disease Control and Prevention’s (Africa CDC) goal of 60% local vaccine production by 2040.
It also supports Egypt’s target of producing 385 million vaccine doses every year by 2030. The initiative will focus on self-amplifying RNA (saRNA)-based vaccines for both human and animal health, employing a One Health approach to bolster defences against zoonotic diseases.
The initiative was announced on the sidelines of the second Vaccine and Other Health Products Manufacturing Forum for African Union member states.
Africa CDC organised the forum and the Egyptian United Procurement Authority hosted it.
By leveraging their combined expertise, the partners aim to deliver scaleable and impactful healthcare solutions in the country and beyond, enhancing regional pandemic preparedness.
EVA Pharma CEO Dr Riad Armanious stated: “Our cross-continental collaboration will empower patients with next-generation, scaleable and versatile solutions that transform what once took years into a process achievable in weeks.”
The development follows an announcement in December 2024 when EVA Pharma and Eli Lilly received approval from the Egyptian Drug Authority for the human insulin glargine injection, designed to treat patients with type 1 and type 2 diabetes.
